Cipla's Pithampur unit gets 8 observations from USFDA after inspection

The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6 - 17

PTI

February 18, 2023 / 19:26 IST

Drug major Cipla on Saturday said the US health regulator has issued Form 483 with eight observations after inspecting its Pithampur-based manufacturing facility in Madhya Pradesh.

The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6 - 17, the Mumbai-based drug firm said in a regulatory filing.

On conclusion of the inspection, the company has received 8 inspectional observations in Form 483, it added.

The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time, it said.

PTI

first published: Feb 18, 2023 07:26 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347